SCHEMBL13430799

SCHEMBL13430799

CNc1ccc(C(N)=O)[nH]1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NNMT P40261 4/20 0.39
ALDH1A1 P00352 3/20 0.38
KDM4E B2RXH2 2/20 0.38
GLA P06280 2/20 0.38
GAA P10253 2/20 0.38
MKNK1 Q9BUB5 1/20 0.36
MAP2K1 Q02750 1/20 0.35
CCNC P24863 3/20 0.34
CDK8 P49336 3/20 0.34
POLB P06746 1/20 0.33
MTNR1A P48039 1/20 0.33
MTNR1B P49286 1/20 0.33
CA1 P00915 1/20 0.32
CA2 P00918 1/20 0.32
PARP1 P09874 1/20 0.32
PARP10 Q53GL7 1/20 0.32
PARP2 Q9UGN5 1/20 0.32
PARP4 Q9UKK3 1/20 0.32
HASPIN Q8TF76 1/20 0.32
HTT P42858 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8108947 0.82 GAA (0.55) KDM4EGLAGAAPOLBCA1
SCHEMBL23682709 0.81 PRKCI (0.32) KDM4EGLAGAAKMT2A
SCHEMBL8748881 0.81 KDM4E (0.44) ALDH1A1KDM4EKMT2ASMN1; SMN2
SCHEMBL16214779 0.79 KDM4E (0.32) KDM4EGLAGAA
SCHEMBL18236156 0.79 ALOX15 (0.45) GAACCNCCDK8HTTLIMK1
SCHEMBL3576164 0.77 MAP2K1 (0.46) NNMTALDH1A1KDM4EGLAGAA
SCHEMBL30846960 0.75 PTPN11 (0.41) KDM4EGLAGAAMKNK1MAP2K1
SCHEMBL30086887 0.75 KDM4E (0.42) NNMTALDH1A1KDM4EGLAGAA
SCHEMBL29063211 0.71
SCHEMBL27912682 0.71 MAP2K1 (0.39) NNMTALDH1A1KDM4EGLAGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100099726-A1 INHIBITORS OF PYRUVATE KINASE AND METHODS OF TREATING DISEASE NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2010-04-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100099726-A1 INHIBITORS OF PYRUVATE KINASE AND METHODS OF TREATING DISEASE PDK1, PDK4, PDK3 NNMT 781/4885ALDH1A1 978/4885KDM4E 1017/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.